
==== Front
NPJ Biofilms Microbiomes
NPJ Biofilms Microbiomes
NPJ Biofilms and Microbiomes
2055-5008
Nature Publishing Group UK London

39294159
540
10.1038/s41522-024-00540-6
Article
Christensenella minuta protects and restores intestinal barrier in a colitis mouse model by regulating inflammation
Kropp Camille 12
Tambosco Kevin 1
Chadi Sead 1
Langella Philippe 1
Claus Sandrine P. 2
http://orcid.org/0000-0002-5980-4113
Martin Rebeca rebeca.martin-rosique@inrae.fr

1
1 grid.460789.4 0000 0004 4910 6535 Micalis Institute, AgroParisTech, INRAE, Université Paris-Saclay, 68350 Jouy-en-Josas, France
2 YSOPIA Bioscience, 33076 Bordeaux, France
19 9 2024
19 9 2024
2024
10 8830 11 2023
23 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Christensenella minuta DSM 22607 has recently been suggested as a potential microbiome-based therapy for inflammatory bowel disease (IBD) because it displays strong anti-inflammatory effects both in vitro and in vivo. Here, we aimed to decipher the mechanism(s) underlying the DSM 22607-mediated beneficial effects on the host in a mouse model of chemically induced acute colitis. We observed that C. minuta plays a key role in the preservation of the epithelial barrier and the management of DNBS-induced inflammation by inhibiting interleukin (IL)-33 and Tumor necrosis factor receptor superfamily member 8 (Tnfrsf8) gene expression. We also showed that DSM 22607 abundance was positively correlated with Akkermansia sp. and Dubosiella sp. and modulated microbial metabolites in the cecum. These results offer new insights into the biological and molecular mechanisms underlying the beneficial effects of C. minuta DSM 22607 by protecting the intestinal barrier integrity and regulating inflammation.

Subject terms

Microbiome
Bacteria
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Over the last decade, several studies have highlighted the use of microbiome-derived therapies using a single bacterium as a promising approach to treat chronic inflammatory disorders, such as necrotizing enterocolitis1 and inflammatory bowel diseases (IBD)2–5. IBD is a multifactorial diseases6 characterized by chronic and abnormal activation of the gut immune system, leading to an uncontrolled and deleterious inflammatory response7. Symptoms associated with IBD include abdominal pain, diarrhea, hematochezia, and weight loss8. Moreover, IBD is associated with a depletion of mucus-secreting goblet cells (GC) and a reduction in the intestinal mucus layer9, which is known to negatively impact intestinal homeostasis10. An increase in intestinal permeability has also been observed, which triggers an immunological response that drives intestinal inflammation11. These are also associated with a gut microbiome imbalance characterized by decreases in bacterial richness and diversity12, features that have been suggested to play an important role in the establishment and maintenance of mucosal inflammation13. In fact, an increase in some commensal opportunistic pathogenic bacteria, such as members of the Enterobacteriaceae and Bacteroidaceae families14–18 and a decrease in members of the Lactobacillaceae family and the butyrate-producing genus Faecalibacterium19–22 have been observed in patients suffering from IBD. Clinical studies have also highlighted the strong depletion of the Christensenellaceae family in the gut microbiota of patients with Crohn’s disease (CD) and ulcerative colitis (UC), the two main types of IBD23–25. Of particular interest, a drop in Christensenellaceae has been shown to be predictive of flares in patients with CD, indicating a possible causal relationship between the presence of Christensenellaceae in the gut community and the maintenance of immune homeostasis in the intestinal barrier23.

Modulating the gut microbiota with members of the Christensenellaceae family could be considered as a therapeutic option. For example, it has been shown that in people with a low body mass index (BMI), the Christensenellaceae family was significantly more abundant compared to adults with a hight BMI26. Moreover, Chistensenella minuta DSM 33407, one member of Christensenellaceae family, represents a potential anti-obesity treatment by its capacity to decrease glycemia and free fatty acids in serum and liver respectively in vivo27. C. minuta has been suggested to be a key member of the healthy human gut community28 and has been recently identified as a key component of healthy microbiota29. Keystone species were defined in 1969 as “a specie which has a disproportionately large effect on its natural environment relative to its abundance”30. They play a critical role in maintaining the structure of ecological communities. These taxa, which are highly connected within the ecosystem, play a unique and crucial role in microbial communities, carrying essential functions to support the growth of other species. Their reduction can cause a dramatic shift in microbiome structure and functioning31 as Christensenellaceae family has been described in co-occurrence network analysis as the central member of a hub of microorganisms that includes other heritable taxa26. Maintaining physiological levels of Christensenellaceae in the gut microbiota of patients thus represents an interesting therapeutic strategy for the management of the disease. We have previously demonstrated that C. minuta DSM 22607 exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway in vitro. It also reduced colonic inflammation in vivo in two murine models of induced-colitis32.

Here, we aimed to elucidate the mechanism(s) underlying the immunomodulatory effects of C. minuta DSM 22607 on the host. For this purpose, we analyzed the impact of the administration of C. minuta in a chemical-induced mouse model of colitis (dinitrobenzene sulfonic acid (DNBS)). We focused on the intestinal barrier, including mucus production and permeability, and immunomodulatory effects at local and systemic levels. These effects on the host were complemented by RNA-seq transcriptomic analysis of intestinal tissues and an investigation of microbiota modifications at the taxonomic and functional levels. This study provides new insights into the mechanism of action underlying the anti-inflammatory effects of C. minuta, supporting the multiple benefits of this bacterium in IBD management.

Results

Christensenella minuta DSM 22607 attenuates colitis severity in a DNBS-induced mouse model

To decipher the mechanism of action of C. minuta, we induced colitis in mice using dinitrobenzene sulfonic acid (DNBS). Mice were administered DSM 22607 by gavage 14 days before the induction of inflammation. We validated C. minuta protective effects of C. minuta, as it reduced DNBS-induced weight loss and improved weight recovery (p < 0.001, Supplementary Fig. 1a). Furthermore, DSM 22607 treatment decreased DNBS-induced macroscopic and microscopic damage, as observed by the macroscopic (p < 0.0001) and histological (p < 0.001) scores (Supplementary Fig. 1b, c), and decreased myeloperoxidase (MPO) activity (p = 0.06, Supplementary Fig. 1d), which confirmed the anti-inflammatory effects observed in our previous study32.

DSM 22607 improves intestinal barrier integrity by modulating paracellular pathways and tissue resistance in the colon

We assessed intestinal permeability by measuring bacterial translocation using serum lipopolysaccharide (LPS)-Binding Protein (LBP) as a proxy marker (Fig. 1a). As expected, we observed an increase in LBP in the DNBS-Vehicle group compared with that in the CTRL-Vehicle group (p < 0.0001), reflecting an increase in intestinal permeability. However, no improvements were observed in the DNBS-DSM 22607 group. To better evaluate local intestinal permeability, colon, ileum, and cecum biopsies collected at the endpoint were mounted in Ussing chambers for 120 min. We analyzed both paracellular (fluorescein-5-(and-6)-sulfonic acid (FSA) and isothiocyanate (TRITC)-dextran) and transcellular peroxidase (horseradish peroxidase (HRP)) permeabilities. A significant decrease in the passage of TRITC-dextran (at 90 min, p < 0.05; at T120 min, p < 0.001) and FSA (at 120 min, p < 0.05) was observed in the colon of DSM 22607-treated mice compared to that in inflamed control mice (Fig. 1b, c), indicating differences in paracellular permeability. In contrast, no significant effects were observed in HRP measurements, indicating no differences in transcellular permeability (Fig. 1d). No significant differences were observed in ileum or cecum sections (Supplementary Fig. 2). Transepithelial electrical resistance (TEER) was recorded across the colon samples (Fig. 2a, b). As expected, TEER was lower in DNBS-treated inflamed mice than in non-inflamed mice. Interestingly, this was partially restored in DSM 22607-treated biopsies compared to the untreated inflamed group (p = 0.079), confirming the potential of DSM 22607 to limit tissue alteration of permeability.Fig. 1 C. minuta maintained intestinal barrier integrity by modulating permeability.

Lipopolysaccharide (LPS) binding protein (LBP) in the serum (a). CTRL-Vehicle (N = 20; white); DNBS-Vehicle (N = 19; dark gray); DNBS-DSM 22607 (N = 19; green). Ussing chamber kinetics of tetramethylrhodamine isothiocyanate (TRITC)-dextran (b), fluorescein-5-(and-6)-Sulfonic Acid (FSA) (c), and horseradish peroxidase (HRP) (d) in colon. CTRL-Vehicle (N = 9; light gray); DNBS-Vehicle (N = 12; dark gray); DNBS-DSM 22607 (N = 12; green). Data are means and standard error of the mean (SEM). Results of the Original FDR method of Benjamini and Hochberg multiple comparison tests comparing the DNBS-Vehicle group to the other three groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Fig. 2 Colonic permeability tended to improve following C. minuta treatment.

During 2 h, raw transepithelial electrical resistance recording (a) and associated aera under the curve (b) were obtained using Ussing chambers. CTRL-Vehicle (N = 9; light gray); DNBS-Vehicle (N = 12; dark gray); DNBS-DSM 22607 (N = 12; green). Data are means and SEM. Results of Original FDR method of Benjamini and Hochberg multiple comparison tests comparing the DNBS-Vehicle group to the two other groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

DSM 22607 improves intestinal barrier structure and function by hampering GC depletion and increasing mucin 2 (MUC2) expression

To evaluate the effects of DSM 22607 on the intestinal barrier, we decided to further analyze the epithelial structure with a focus on the GC and mucus layer. First, as GC depletion is characteristic of DNBS-induced colitis33, we quantified GC populations in the colon using alcian blue (AB) staining. As expected, a decrease in AB-positive cells was observed following DNBS injection (p < 0.0001), whereas C. minuta DSM 22607 prevented the loss of mucus-producing cells (p < 0.0001; Fig. 3a). To determine mucus layer thickness, MUC2 staining, one of the major mucins in the mucus in the colon, was performed. We observed that DSM 22607 treatment significantly improved the thickness of this layer compared to that in the DNBS-Vehicle group (p < 0.05, Fig. 3b).Fig. 3 DSM 22607 improves mucus production by decreasing goblet cell depletion.

AB positive cells/Crypt (a), goblet cell staining (b), thickness of the mucus layer (c) and MUC2 staining showed with white arrows (d) in the colon. CTRL-Vehicle (N = 26; white); DNBS-Vehicle (N = 29; dark gray); DNBS-DSM 22607 (N = 31; green). Data are means and SEM. Length of scale bar measured 20 µm. Results of Original FDR method of Benjamini and Hochberg multiple comparison tests comparing the DNBS-Vehicle group to the two other groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

C. minuta DSM 22607 displayed anti-inflammatory effects at local and systemic levels

In the colon, DNBS injection stimulated the protein expression of interleukin (IL)-1α (Fig. 4a), IL-1β (Fig. 4b), and monocyte chemoattractant protein (MCP)-1 (Fig. 4c). DSM 22607 showed anti-inflammatory properties through a significant reduction in IL-1α (p < 0.05) and MCP-1 (p < 0.01) levels, whereas no effects were observed for IL-1β. No significant effects were observed for tumor necrosis factor (TNF)-α, interferon (IFN), γ and IL-23 (data not shown). IL-12p70, IL-10, IL-6, IL-27, IL-17A, and IFNβ and granulocyte-macrophage colony-stimulating factor (GM-CSF) were not detected.Fig. 4 Anti-inflammatory properties of Christensenella minuta at local level.

Determination of IL-1α (a), IL-1β (b) and MCP-1 (c) cytokines in the colon. CTRL-Vehicle (N = 20; white); DNBS-Vehicle (N = 19; dark gray); DNBS-DSM 22607 (N = 19; green). Data are means and SEM. Results of Original FDR method of Benjamini and Hochberg multiple comparison tests comparing the DNBS-Vehicle group to the three other groups.*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

To evaluate the immunomodulatory effects of DSM 22607 at the systemic level, we measured cytokine levels in serum samples and in PMA-IONO-stimulated splenocytes, which activate Th cells. We observed a significant increase in the serum levels of TNF-α (Fig. 5a), IFNγ (Fig. 5b), and MCP-1 (Fig. 5c) following DNBS injection (p < 0.05), which tended to be counterbalanced by DSM 22607 treatment for TNF-α and IFNγ (p = 0.08) and decreased MCP-1 (p < 0.05). No significant effects were observed for IL-1α and IL-23 (data not shown). IL-12p70, IL-1b, IL-10, IL-6, IL-27, IL-17A, and GM-CSF were not detected in these samples. Cytokine measurement of the supernatant of stimulated splenocytes showed that DSM 22607 decreased TNF-α (p < 0.05; Fig. 5d), IL-4 (p < 0.05; Fig. 5e), IL-5 (p < 0.05; Fig. 5f), and IL-6 (p < 0.01; Fig. 5g) levels compared with the DNBS-vehicle group. No differences were observed in IFNγ, IL-2, IL-10, IL-17A, and IL-22 cytokines between the groups (data not shown). IL-9, IL-17F, and IL-13 were not detected (data not shown).Fig. 5 Anti-inflammatory properties of Christensenella minuta at systemic levels in serum and spleen.

Determination of TNF-α (a); IFNγ (b); and MCP-1 (c) cytokines in serum. Following splenocyte stimulation, TNF-α (d), IL-4 (e), IL-5 (f) and IL-6 (g) were measured. CTRL-Vehicle (N = 20; white); DNBS-Vehicle (N = 19; dark gray); DNBS-DSM 22607 (N = 19; green). Data are means and SEM. Results of Original FDR method of Benjamini and Hochberg multiple comparison tests comparing the DNBS-Vehicle group to the three other groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

DSM 22607 modulates gut microbiota composition

To assess the modulation of the gut microbiota following C. minuta administration and DNBS injection, we collected feces at time (T) T0 (before any treatment), T14 (14 days after gavage with C. minuta or controls), and fecal content at T17 (3 days post-injection and final time point). After quality control, there were a total of 4,678,378 reads, and a mean of 27,358 reads per sample (min = 20,132 and max = 34,377). A total of 982 amplicon sequence variants (ASVs) were identified. The assessment of microbiota diversity indices at each time point revealed no significant differences between T0 and T14 (Supplementary Fig. 3a, b, d, and e) between groups. Neither alpha nor beta diversity was impacted. Conversely, significant changes were observed at the end of the experiment (T17). The most significant differences were detected between the inflamed (DNBS-vehicle and DNBS-DSM 22607) and non-inflamed (CTRL-vehicle) groups. The inflamed groups showed a significantly lower alpha diversity (Supplementary Fig. 3c), and increased dissimilarity compared to that in the non-inflamed groups (Supplementary Fig. 3f). This result indicates that inflamed gut microbial communities are less diverse and more heterogeneous, displaying the most dissimilar communities among individuals of the same group.

A differential abundance analysis that identified significant differences in the gut microbiota composition at the family level was performed. Members of Enterobacteriaceae (p < 0.05; Fig. 6a), Porphyromonadaceae (Fig. 6b), Mogibacteriaceae (p < 0.05; Fig. 6c), Bacteroidaceae (p < 0.01; Fig. 6d), and Enterococcaceae (p = 0.07; Fig. 6e) were higher in the inflamed group than in the control group. In contrast, Lactobacillaceae (p < 0.01; Fig. 6f), Lachnospiraceae (p < 0.01; Figs. 6g), S24–6 (p < 0.001; Fig. 6h), and Turicibacteraceae (p < 0.05; Fig. 6i) decreased in the DNBS-vehicle group. Members of the Christensenellaceae family were exclusively present in the DNBS-DSM 22607 group (p < 0.0001; Fig. 6j), where they were present in a concentration higher of the detection limit in 10 of 16 animals. By using a specific set of primers, we confirmed the presence of C. minuta at the end of the experiment (D21) on the same gDNA by PCR in all the mice (data not shown). We also detected a higher abundance of members of the families Verrucomicrobiaceae (p = 0.053; Fig. 6k), Rikenellaceae (p < 0.05; Fig. 6l), and Coriobacteriaceae (p < 0.05; Fig. 6m) in the DNBS-DSM 22607 group.Fig. 6 Amplicon sequence variant (ASV) family diversity among groups at the experiment end.

Enterobacteriaceae (a), Prophyromonadaceae (b) Mogibacteriaceae (c), Bacteroidaceae (d), Enterococcaceae (e), Lactobacillaceae (f), Lachnospiraceae (g), S24-7 (h), Rikenellaceae (i), Turibacteraceae (j), Christensenellaceae (k), Verrucomicrobiaceae (l) and Coriobacteriaceae (m) ASVs at the end of the experiment. CTRL-Vehicle (N = 20; white); DNBS-Vehicle (N = 19; dark gray); DNBS-DSM 22607 (N = 19; green). Data are means and SEM. Results of Original FDR method of Benjamini and Hochberg multiple comparison tests comparing the DNBS-Vehicle group to the three other groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

We further examined the correlation between the relative abundances of C. minuta and other genera in the DNBS-DSM 22607 group. The high relative abundances of Akkermansia sp. and Dubosiella sp. were slightly positively correlated with the presence of the Christensenella genus (Figs. 7a and 7b), as illustrated by the correlation coefficients of R2 = 0.1269 (p = 0.0073) and R2 = 0.2661 (p < 0.0001), respectively. Interestingly, an increase in these two genera, compared to DNBS-Vehicle, was only observed in mice in which we detected the Christensenellaceae family in the differential abundance analysis (data not shown).Fig. 7 Positive correlation between Christensenella and Akkermansia and Dubosiella genus.

Akkermansia (a) and Dubosiella (b) amplicon sequence variant (ASV) abundances versus Christensenella. Results correlation with Pearson r test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Modulation of microbial metabolites by DSM 22607

Modulation of short chain fatty acids (SCFA) production in the cecum was measured using gas chromatography. The three main SCFAs found in the gut are acetate (Fig. 8a), butyrate (Fig. 8b), and propionate (Fig. 8c). DNBS induced a decrease in these three SCFAs compared to that in the CTRL-vehicle group. In contrast, an increase in SCFAs was observed in the C. minuta DSM 22607 group (p < 0.05), mitigating the effects of DNBS-induced inflammation on these metabolites. A similar effect was observed for valerate (p < 0.01; Fig. 8d). For both branched chain fatty acids (BCFA), isobutyrate (Fig. 8e), and isovalerate (Fig. 8f), no effects were observed following treatment with C. minuta.Fig. 8 C. minuta increases cecal short chain fatty acid (SCFA) production.

Assessment of acetate (a); butyrate (b); propionate (c); valerate (d); isobutyrate (e) and isovalerate (f) production in the cecum. CTRL-Vehicle (N = 26; white); DNBS-Vehicle (N = 29; dark gray); DNBS-DSM 22607 (N = 31; green). Data are means and SEM. Results of the Original FDR method of Benjamini and Hochberg multiple comparison tests comparing the DNBS-Vehicle group to the other three groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

DSM 22607 modulates inflammatory and functional genes in the colon

RNA samples (CTRL-Vehicle (N = 20); DNBS-Vehicle (N = 19)); DNBS-DSM 22607 (N = 19) were sequenced with a yield of 50 million reads per sample. Multivariate discriminant analysis using an sPLS-DA approach enabled the identification of the top 100 genes (Table 1) that discriminated the inflamed groups DNBS-DSM 22607 and DNBS-Vehicle: 82 downregulated and 18 upregulated by DSM 22607. We observed that our treatment reduced the expression of genes involved in inflammation (Tnfrsf8 and Atg5), mitochondrial membrane (Tomm7 and Tmem126a), cell migration, and tumorigenesis (Sn x 16). To validate the transcriptomic analysis, we performed RT-qPCR analysis of two genes that were found to be modulated and associated with the observed phenotype: one involved in inflammation, a member of the TNF receptor family (Tnfrsf8), and the other linked to cell-cell adhesion (Jup, a plakoglobin protein that is a component of adherent junctions and desmosomes). We performed this quantification in the colon samples. As expected, Tnfrsf8 was significantly decreased (p < 0.05; Fig. 9a), and Jup was significantly increased (p < 0.01; Fig. 9b) in the DNBS-DSM 22607 group. These results validated the results of transcriptome analysis and led us to continue investigating the mechanisms of action of C. minuta.Table 1 Top 100 genes modulated by DSM 22607 compared to DNBS-vehicle via sPLS-DA approach

GeneID	SYMBOL	logFC	adj.P.Val	GeneID	SYMBOL	logFC	adj.P.Val	
ENSMUSG00000028602	Tnfrsf8	−0,99743626	0,29510731	ENSMUSG00000002580	Mien1	−0,22417223	0,30891771	
ENSMUSG00000047854	Stx19	−0,72030651	0,27035889	ENSMUSG00000024293	Esco1	−0,22040676	0,20828067	
ENSMUSG00000023919	Cenpq	−0,46702204	0,30891771	ENSMUSG00000025967	Eef1b2	−0,21902614	0,28500164	
ENSMUSG00000114540	NA	−0,44988898	0,34684554	ENSMUSG00000078970	Wdr92	−0,21818105	0,30760988	
ENSMUSG00000096010	H4f16	−0,43470579	0,30891771	ENSMUSG00000037531	Mrpl47	−0,2173443	0,30891771	
ENSMUSG00000114456	H2bc9	−0,42550252	0,29950651	ENSMUSG00000022370	Mrpl13	−0,21664537	0,29951729	
ENSMUSG00000078974	Sec61g	−0,41581979	0,25057889	ENSMUSG00000063362	Alg11	−0,21499792	0,19625406	
ENSMUSG00000030521	Mphosph10	−0,38416676	0,30760988	ENSMUSG00000026568	Mpc2	−0,21294554	0,27611749	
ENSMUSG00000036781	Rps27l	−0,37678571	0,22844889	ENSMUSG00000001891	Ugp2	−0,21110044	0,30891771	
ENSMUSG00000052033	Pfdn4	−0,37455825	0,28500164	ENSMUSG00000031696	Vps35	−0,21053581	0,28118045	
ENSMUSG00000032330	Cox7a2	−0,36291934	0,20828067	ENSMUSG00000020076	Ddx50	−0,21023024	0,20828067	
ENSMUSG00000028175	Depdc1a	−0,3620709	0,33499303	ENSMUSG00000054302	Eapp	−0,20672131	0,23936558	
ENSMUSG00000062328	Rpl17	−0,32598048	0,27035889	ENSMUSG00000034800	Zfp661	−0,20642286	0,3849899	
ENSMUSG00000028295	Smim8	−0,3238612	0,27755867	ENSMUSG00000020397	Med7	−0,20403306	0,29510731	
ENSMUSG00000069208	Zfp825	−0,31927764	0,27035889	ENSMUSG00000029462	Vps29	−0,20114252	0,30891771	
ENSMUSG00000030469	Zfp719	−0,31692917	0,19305783	ENSMUSG00000026500	Cox20	−0,19770674	0,34568622	
ENSMUSG00000058291	Zfp68	−0,30754312	0,25057889	ENSMUSG00000046603	Tcaim	−0,1971252	0,29969993	
ENSMUSG00000003198	Zfp959	−0,30357571	0,29142092	ENSMUSG00000040044	Orc3	−0,19574769	0,25900506	
ENSMUSG00000032673	Prorsd1	−0,29841183	0,25057889	ENSMUSG00000037075	Rnf139	−0,19447024	0,27035889	
ENSMUSG00000027534	Snx16	−0,29345952	0,27575137	ENSMUSG00000026577	Blzf1	−0,18959363	0,30891771	
ENSMUSG00000074521	NA	−0,29060099	0,39568849	ENSMUSG00000051469	Zfp24	−0,18958995	0,19305783	
ENSMUSG00000031347	Cetn2	−0,28992334	0,25406939	ENSMUSG00000025979	Mob4	−0,18572347	0,29950651	
ENSMUSG00000027835	Pdcd10	−0,28964885	0,26112428	ENSMUSG00000027937	Jtb	−0,18161537	0,29510731	
ENSMUSG00000048495	Tyw5	−0,28875924	0,27035889	ENSMUSG00000066880	Zfp617	−0,18004659	0,28118045	
ENSMUSG00000021290	Atp5mpl	−0,28574474	0,20828067	ENSMUSG00000031479	Vps36	−0,17721061	0,27040179	
ENSMUSG00000041153	Osgin2	−0,27926591	0,29510731	ENSMUSG00000041124	Msantd4	−0,17512831	0,30891771	
ENSMUSG00000068882	Ssb	−0,27668082	0,25057889	ENSMUSG00000021023	Prorp	−0,17440299	0,34376946	
ENSMUSG00000070394	Tmem256	−0,27331311	0,26728859	ENSMUSG00000071267	Zfp942	−0,17016226	0,4057334	
ENSMUSG00000042670	Immp1l	−0,27226643	0,30891771	ENSMUSG00000036299	BC031181	−0,16428556	0,34376946	
ENSMUSG00000021711	Trappc13	−0,26365975	0,19305783	ENSMUSG00000027088	Phospho2	−0,16215153	0,35840453	
ENSMUSG00000078994	Zfp429	−0,26043082	0,30760988	ENSMUSG00000037860	Aim2	−0,16038052	0,40282073	
ENSMUSG00000073448	NA	−0,25843035	0,34906971	ENSMUSG00000017686	Rhot1	−0,15711633	0,2254286	
ENSMUSG00000028998	Tomm7	−0,25808785	0,27035889	ENSMUSG00000001552	Jup	0,308949158	0,19625406	
ENSMUSG00000078862	Gm14326	−0,25441179	0,32043191	ENSMUSG00000039910	Cited2	0,388552298	0,25900506	
ENSMUSG00000026021	Sumo1	−0,25411878	0,19625406	ENSMUSG00000002763	Pex6	0,389786576	0,19305783	
ENSMUSG00000021022	Ppp2r3c	−0,25270256	0,28118045	ENSMUSG00000000631	Myo18a	0,42506165	0,19305783	
ENSMUSG00000030615	Tmem126a	−0,25162666	0,25057889	ENSMUSG00000020747	Tmem94	0,434966894	0,20828067	
ENSMUSG00000045624	Esf1	−0,25147634	0,30891771	ENSMUSG00000037686	Aspg	0,453762602	0,27035889	
ENSMUSG00000116802	Gm5165	−0,24678902	0,33565587	ENSMUSG00000044707	Ccnjl	0,471308593	0,29510731	
ENSMUSG00000028563	Tm2d1	−0,24532911	0,30891771	ENSMUSG00000022199	Slc22a17	0,4767096	0,25057889	
ENSMUSG00000039270	Megf9	−0,24455218	0,30891771	ENSMUSG00000022096	Hr	0,540875898	0,21432634	
ENSMUSG00000040374	Pex2	−0,24419174	0,25057889	ENSMUSG00000048916	NA	0,554931734	0,28996021	
ENSMUSG00000024145	Pigf	−0,2437491	0,30891771	ENSMUSG00000097336	Fendrr	0,585339795	0,20828067	
ENSMUSG00000053289	Ddx10	−0,24056409	0,28255213	ENSMUSG00000045348	Nyap1	0,598431945	0,29510731	
ENSMUSG00000033983	Coil	−0,23576517	0,28118045	ENSMUSG00000064345	ND2	0,64893192	0,28527504	
ENSMUSG00000002728	Naa20	−0,23397621	0,28118045	ENSMUSG00000038473	Nos1ap	0,66887166	0,28118045	
ENSMUSG00000038160	Atg5	−0,22954702	0,22844889	ENSMUSG00000110772	NA	0,701002337	0,28500164	
ENSMUSG00000074781	Ube2n	−0,22927426	0,25057889	ENSMUSG00000090561	NA	0,739140612	0,36375605	
ENSMUSG00000038628	Polr3k	−0,22897652	0,23936558	ENSMUSG00000109325	NA	0,75294619	0,30891771	
ENSMUSG00000062931	Zfp938	−0,22658542	0,35840453	ENSMUSG00000108365	NA	1,005271021	0,27035889	

Fig. 9 C. minuta significantly modulated Tnfrsf8 and Jup gene expressions.

Tnfrsf8 (a) and Jup (b) gene expression in the colon. CTRL-Vehicle (N = 26); DNBS-Vehicle (N = 29); DNBS-DSM 22607 (N = 31). Data are means and SEM. Results of the Original FDR method of Benjamini and Hochberg multiple comparison tests comparing the DNBS-Vehicle group with the other two groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Finally, transcriptomic results were analyzed using ingenuity pathway analysis (IPA) software. Analysis of upstream regulators and networks showed inhibition of il-33 and siglec8 following DSM 22607 administration. Interestingly, il-33 and tfnrsf8 expression depends on the same transcription regulator, MYF6, and is linked to the MyD88 pathway (Fig. 10). Therefore, we quantified il-33 and myd88 gene expression in the colon by qPCR, which is linked to the activation of the pro-inflammatory NF-κB pathway34,35. We observed that DSM 22607 decreased il-33 (p < 0.05; Fig. 11a) without modulating myd88 gene expression (Fig. 11b).Fig. 10 Casual network involved in DSM 22607 effects.

Legend: Leads to an inhibition (blue); findings inconsistent with state of downstream molecule (yellow); effect not predicted (gray); inhibition induced by DSM 22607 (purple). Activation, causation or expression (entire arrow); indirect interaction (streaked arrows). Cytokine (square); transmembrane receptor (oval); transcription regulator (elongated oval); other (circle). Decreased measurement (green oval); predicted inhibition (blue oval).

Fig. 11 C. minuta inhibited IL-33 pathway independently of MyD88 gene expression.

IL-33 (a) and MyD88 (b) gene expression in the colon. CTRL-Vehicle (N = 26; white); DNBS-Vehicle (N = 29; dark gray); DNBS-DSM 22607 (N = 31; green). Data are means and SEM. Results of Original FDR method of Benjamini and Hochberg multiple comparison tests comparing the DNBS-Vehicle group to the two other groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Discussion

One promising innovative approach for the management of IBD is the use of microbiome-based therapies. Thus, the use of a single keystone bacterium from the human intestinal microbiota, such as C. minuta is an interesting therapeutic option to complement existing treatments that fail to address underlying gut microbial dysbiosis. Consequently, following the discovery of C. minuta anti-inflammatory properties of C. minuta in both in vitro and in vivo models32, our objective was to further explore its mechanisms of action.

First, we determined the effects of C. minuta extract on the structure of the intestinal barrier. In a previous study, C. minuta DSM 22607 partially restored permeability in an in vitro model of intestinal cells, whereas no improvements were observed in DNBS-induced systemic hyperpermeability in vivo32. To assess local intestinal permeability in vivo, we tested colon, ileum, and cecum permeability in Ussing chambers after DNBS challenge. Two permeability pathways were measured: (i) paracellular, which can result from dysregulated tight junction (TJ) protein expression and (ii) transcellular, which is defined as passive diffusion through cells36. We observed a significant effect of C. minuta DSM 22607 on the paracellular pathway but not on the transcellular pathway. IBD is associated with dysfunction of the paracellular pathway, increasing permeability due to TJs dysfunction (i.e., Claudin or Occludin) and other junctional complexes such as desmosomes11,37. In addition, colonic TEER was increased after DSM 22607 administration, confirming the improvement of paracellular permeability, since 90% of the total TEER in the colonic tissue is due to the paracellular pathway38. It has recently been reported that probiotics such as Bifidobacterium bifidum could play a role in TJs regulation in animal models of colitis in a TLR-2-dependent manner, compensating for the deleterious effects induced by DNBS39. Interestingly, we observed upregulation of Jup expression, a gene involved in the regulation of cell-cell adhesion, such as desmosomes and E-cadherin adhesion complexes (UniProtKB, Q02256), which are essential proteins regulating the paracellular pathway. In addition, it has been demonstrated that desmosome adhesion during IBD plays a major role to stabilize and reverse intestinal permeability40. The mucus layer is another essential component of the intestinal barrier structure41. DSM 22607 treatment prevented the depletion of mucus-producing cells induced by DNBS, a trait also observed in IBD patients33. MUC2 staining confirmed that C. minuta DSM 22607 limited mucus thinning in the colon. These results corroborate that DSM 22607 can limit intestinal damage during IBD by protecting the intestinal barrier.

The intestinal epithelial barrier is also composed of an inner layer known as the lamina propria which hosts numerous immune cells42. Previously, we observed that DSM 22607 has anti-inflammatory effects in vitro by decreasing IL-8 cytokine production in TNF–α stimulated HT-29 cells and in vivo by reducing MPO activity in a murine colitis model32. Thus, we monitored the immunomodulatory effects of DSM 22607 at local and systemic levels. At the local level, we observed a decrease in colonic IL-1α and MCP-1 levels, two cytokines involved in IBD43,44. MCP-1 is induced by TNF-α and is involved in macrophage recruitment45. Interestingly, macrophages are known to release IL-1α, which suggests that the observed decrease in the colon may be due to lower macrophage infiltration46. This finding is consistent with the beneficial ability of some bacteria to modulate inflammation. For example, Akkermansia muciniphila has been shown to decrease inflammation in the colon through the reduction of MCP-1 release in a DSS-induced colitis model47. Other probiotics have also demonstrated the ability to prevent the synthesis of pro-inflammatory cytokines, such as IL-8, TNF-, α and MCP-1, in UC patients48. At a systemic level, we observed that C. minuta treatment led to a decrease in MCP-1 and tended to decrease IFNγ and TNF-α cytokines in the serum, indicating a systemic immunomodulatory effect. Thus, to characterize the adaptive immune response, which is known to play an important role in IBD49, we evaluated cytokine release by activated lymphocytes in the spleen. We observed a decrease in TNFα and, interestingly, a decrease in IL-4, IL-5, and IL-6. The spleen is a secondary lymphoid tissue involved in the main immune response, and its function is affected during IBD50. TNF-α, produced by M1 macrophages, is known to be a major Th1 cytokine in IBD, with pro-inflammatory effects51. To manage inflammation, anti-TNF-α therapy has been developed to hamper the pro-inflammatory response in IBD52. Moreover, the reduction of TNF-α, an inducer of the NF-κB inflammatory pathway53 following C. minuta administration is consistent with the previous observation of the inhibition of the NF-κB pathway32. Researchers have also highlighted a high prevalence of allergic diseases in patients with CD54, associated with Th2 cytokines, such as IL-4, IL-5, and IL-655. The decrease in IL-4 suppresses the development of colitis in mice56 and the inhibition of IL-6 induces immunosuppression in patients57. These results showed that DSM 22607 displayed strong anti-inflammatory properties and confirmed its immunomodulatory potential.

Gut microbiota, a component of the intestinal barrier, is altered during IBD12. Therefore, we hypothesized that C. minuta DSM 22607 could exert some protective effects through the modulation of the gut microbiota and observed that DNBS induced a decrease in gut microbiota richness and diversity, including an increase in some bacterial families such as Enterobacteriaceae and Bacteroidaceae and a decrease in Lactobacillaceae family. All these modulations have also been previously reported in IBD in humans and mouse colitis models16–18,22. Interestingly, C. minuta administration was correlated with the abundance of Akkermansia spp., a genus widely documented for its positive action on the gut barrier58 and Dubosiella sp., shown to be positively correlated with the increase of butyric acid and negatively correlated with IL-1b and IL-6 mRNA expressions in a DSS mouse colitis model59. Recently, the presence of these two species was reported to be positively correlated: following oral administration of pasteurized A. muciniphila, the authors observed a significant increase in Dubosiella sp., thereby alleviating intestinal damage induced by DSS in mice60. These microbial modulations are associated with functional modifications, as illustrated by the changes in SCFAs production. DSM 22607 treatment increased the levels of butyrate, acetate, propionate, and valerate in the cecum. DSM 22607 is a high acetate and low butyrate producer32 and a recent study showed that the addition of C. minuta DSM 33407 was sufficient to stimulate the production of acetate, butyrate and propionate, known as the three main SCFAs27. The increase in Akkermansia and Dubosiella could also help explain the restoration of SCFA levels as butyrate, acetate, and propionate by modulating microbial metabolism and downregulating Th1 cytokines in the colon61. Interestingly, acetate and butyrate were associated with MUC2 expression in a dose-dependent manner62. Acetate is also involved in GC differentiation through the activation of the KLF4 transcription factor63; butyrate is well known to have anti-inflammatory effects, notably by inhibiting the NF-κB pathway64. Therefore, it is possible that the increased production of these SCFAs largely contributes to other protective effects on the intestinal barrier observed following C. minuta treatment. Christensenellaceae is considered as a gut microbiota keystone species known to held a role as a hub in a co-occurrence network that includes heritable taxa26. Multiple studies indicate that Akkermensia spp., Dubosiella spp., Christensenellaceae and other families as Rikenellaceae are often positively correlated. For instance, it has been sown that a combination of baicalin and berberine hydrochloride ameliorates Dextran Sulfate Sodium-Induced Colitis by increasing Christensenellaceae and Erysipelotrichaceae (Dubosiella family) and modulating inflammation in a DSS colitis model65. Moreover in 2023, polysaccharides from the seeds Gleditsia sinensis stimulated the abundance of Akkermansia spp. and Christensenella spp. which could be linked to the improvement of intestinal barrier by increasing Muc2 expression, tight junction protein and SCFA amount66. All these information established that C. minuta administration induced several shifts with beneficial effects in our mouse model confirming the importance of this bacterium.

Finally, Tnfrsf8 levels were significantly decreased in the C. minuta-treated group. Tnfrsf8 plays a major role in the management of inflammatory diseases by activating innate and adaptive immune cells34. For example, in a TNBS-induced colitis model, Tnfrsf8 KO mice were resistant to TNBS-associated effects67. Moreover, network analyses revealed that DSM 22607 inhibits IL-33 and SIGLEC 8, both of which are associated with pro-inflammation. IL-33, which activates SIGLEC 8-mediated apoptosis68, is a member of the IL-1 family that induces T cell differentiation into Th1 cells, maturation of dendritic cells, upregulation of natural killer (NK) cells, and CD8+ cells35 and drives type 2 innate lymphoid cells in allergy69. However, here, IL-33 expression in the colon was not regulated via Myd88. Other studies have observed a role of IL-33 due to microbiota modulation during inflammation. The administration of A. muciniphila has been found to restore the diversity of the intestinal microbiota depleted during abdominal aortic aneurysms and reduced markers of inflammation such as IL-3370. In contrast, Arifuzzaman and co workers showed recently that inulin-induced gut microbiota modifications, which altered microbiota-derived metabolites as bile acids and enhanced the expression of IL-3371. More studies should be performed to determine which is the mechanism that allow C. minuta to decrease IL-33 production.

In conclusion, our research confirmed the protective effects of C. minuta DSM 22607 on the intestinal epithelial barrier and its anti-inflammatory effects in a rodent model of IBD. This study also provides new insights into the mechanisms of action of C. minuta DSM 22607 and further supports the need for a clinical trial to validate the use of C. minuta strains as a microbiome-based therapy to manage IBD.

Methods

Bacteria growth conditions

Christensenella minuta DSM 22607 was grown in GAM broth modified medium (HyServe, Germany) as described by Kropp et al.32. Briefly, after revivification of a stock for 4 days at 37 °C under anaerobic conditions, a preculture was obtained from a single colony grown in GAM for 2 days. Finally, to prepare gavage aliquots, this preculture was used to inoculate the final culture under the same conditions. The culture was centrifuged at 2500 g during 20 min, washed in phosphate-buffered saline 1X (PBS) (Gibco, Thermo Fisher Scientific, USA), resuspended in PBS with 16% glycerol (PBS/glycerol) at 5 *109 CFU/mL, and stored at -80°C until use.

Mouse model experimental design

Eighty-eight 7-week-old male C56BL/6 J mice were obtained from Janvier Lab and maintained under specific pathogen-free (SPF) conditions in the animal facilities of the National Research Institute for Agriculture, Food and Environment (IERP, INRAE, Jouy-en-Josas, France). The experiments were performed in two separate batches, and the mice were housed in cages of 4 or 5. All animal experiments were performed in accordance with the European Community Guidelines for Animal Care. Animal care and work protocols were approved by the local regional ethical committee Comethea according to EU Directive 2010/63/EU. After 7 days of acclimation, the mice were divided into three groups: control non-inflamed mice which received 150 µL of PBS/glycerol solution (vehicle) by oral gavage (CTRL-Vehicle, n = 26); control inflamed mice that received 150 µL of vehicle by oral gavage (DNBS-Vehicle, n = 30), treated mice that received C. minuta DSM 22607 at 109 CFU/mL by oral gavage (DNBS-DSM 22607, n = 32). Two weeks after the start of daily force-feeding, the mice were anesthetized by intraperitoneal injection of 0.1% ketamine and 0.06% xylazine and received by intra rectal injection a solution of 165 mg/kg DNBS dissolved in ethanol 30%. The control group without inflammation (CTRL-Vehicle) received an intra rectal injection with a solution of ethanol 30%. Three days after DNBS injection, the mice were euthanized by cervical dislocation just after taking a terminal blood sample from the submandibular vein. Body weight variation was monitored daily, and macroscopic and microscopic scores were obtained as previously described32. Briefly, a 1 cm piece of colon was collected and fixed for 24 h in a 4% paraformaldehyde (PFA) solution before dipping it in 70% ethanol. Samples were embedded in paraffin using a tissue embedding system (Leica), cut into 5 μm sections using a microtome (UC6, Reicher E - Leica UC6), and then stained with hematoxylin and eosin (HE) for histological scoring using an automated staining system (Leica). Tissue sections were evaluated to characterize alterations in mucosal architecture and the degree of immune cell infiltration72. DNBS-induced chronic inflammation is also visible at the macroscopic level, and inflammation intensity can be evaluated by measuring different parameters as damage in colon tissue and stool consistency, using Wallace’s score73 with the following modifications: tissue sections from each mouse were scored by evaluating ulcerations (score of 0–5), adhesions (presence/absence: 0/1), hyperemia (presence/absence: 0/1), altered transit with constipation (presence/absence: 0/1), and increases in colon wall thickness (presence/absence: 0/1; measured using an electronic caliper, Control Company, WVR, United States).

To observe the effect of C. minuta on local permeability, Ussing chamber experiments were performed. Thirty-three 7-week-old C56BL/6 J male mice were obtained from Janvier Lab, maintained under SPF conditions in IERP animal facilities, and housed in cages of 3. Mice were divided into three groups (CTRL-Vehicle: n = 9, DNBS-Vehicle: n = 12, and DNBS-DSM 22607: n = 12) and the same protocol as for the DNBS experiment was followed.

MPO activity determinations

1 cm section of colon was placed in liquid nitrogen and stored at -80°C until MPO dosage to determine inflammation74. Briefly, after adding 300 µl of hexadecyl trimethyl ammonium bromide (HTAB) (Sigma-Aldrich, USA) buffer, tissues were homogenized for three cycles of 30 s at 8000 rpm at 4°C with Precellys® evolution coupled to Cryolys® evolution (Ozyme, France). The samples were centrifuged at 14,000 x g for 5 min, and the supernatants were collected. o-Dianisidine 1% H202 solution (200 µL, Sigma-Aldrich, USA) was added to 6 µL of the samples in a 96-well plate. One hour later, the plates were read using a spectrophotometer at 450 nm (TECAN, Switzerland). The results were normalized to the sample weight.

Measurement of general intestinal permeability in vivo

Blood was collected on the day of necropsy in microtest Kima tubes (Labellians, France) and processed immediately by centrifugation at 2000 g for 10 min at room temperature. Serum was stored at -80°C until use. Lipopolysaccharide (LPS)-binding protein (LBP) (Hycult Biotech, Netherlands) in serum was measured by ELISA according to the manufacturer’s specifications.

Ex vivo local permeability measurement

Three days after DNBS injection, mice were euthanized and the colon, ileum, and cecum were collected; content samples were removed by flushing with cold PBS 1X and immediately mounted in Ussing chambers as described previously75. To assess the para- and trans-cellular permeability, we measured the mucosal-to-serosal flux of three different molecules over 120 min: HRP (40 kDa, type II, Merck, Germany), FSA (500 Da, Thermo Fisher Scientific, USA), and TRITC-dextran (4 kDa, TdB Labs, Sweden). Molecules were added to the mucosal side of the chamber at final concentrations of 200 µg/mL, 40 µg/mL, and 400 µg/mL. The electrical part was assessed by clamping the voltage and recording the change in conductance (G) and resistance (Ω) over 2 h. The results are expressed as conductivity and resistance per second and represented by the area under the curve of these measurements.

Staining of mucus producing cells and MUC2 determinations

One centimeter section of the colon was fixed for at least 3 weeks in water-free methacarn solution76. The tissues were then embedded in paraffin (VWR, USA), and sections were cut using a microtome (Leica, USA). AB staining was performed to color the mucins present in GC, according to standard protocols. To avoid bias, the % of positive AB cells in each crypt was normalized to the total cell count. For MUC2 determination, immunohistochemistry was performed according to standard methods using Leica BOND RXm. The protocol included a deparaffinization and rehydration step, an acidic antigen retrieval step (20 min at 100°C in BondTM Epitope Retrieval 1), and blocking with 1% BSA and 10% Normal Goat Serum for 30 min at room temperature. The primary antibody anti-MUC2 (dilution 1/500, Novus Biological, USA) was applied to the slides for 1 h at room temperature, and anti-rabbit secondary antibody ((dilution 1/200, Goat anti-Rabbit IgG (H + L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 568, Invitrogen, USA) with DAPI) was added for 30 min at room temperature. The slides were mounted using Fluoromount® (Cliniscience, France). All slides were scanned using a Pannoramic SCAN II automated slide scanner (3D HISTECH, Hungary) at 20X and analysed using Caseviewer software.

Cytokine determinations

Cytokines were measured locally in the colon and at systemic levels in serum samples using the LEGENDplex mouse inflammation panel IL-1α, IL-1β, IL-6, IL-10, IL-12p60, IL-16A, IL-23, IL-26, MCP-1, IFN-β, IFN-γ, TNF-α, and GM-CSF (BioLegend, USA) according to the manufacturer’s instructions. The samples were analyzed using a flow cytometer Accuri C6 (BD Biosciences, USA). Samples were analyzed using LEGENDplex software according to the data analysis software suite manual (legendplex.qognit.com; Supplementary Figure 5). For colonic concentrations, the results were normalized based on tissue weight.

Spleen cells stimulation

Spleens were collected in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Thermo Fisher Scientific, USA) and kept on ice. Spleens were smashed in a 40 µm sterile cell strainer (Falcon®), and cells were collected in 2 mL mL DMEM supplemented with 10% fetal calf serum (FCS) (Eurobio Scientific, France) and 1% penicillin/streptomycin cocktail (Sigma-Aldrich, USA). The spleens were centrifuged at 300 g for 10 min at 4°C. Supernatants were removed and 1 mL of 1X red blood cell lysis buffer was added to lyse the erythrocytes. After 5 min, complete DMEM was added to stop the reaction and the samples were centrifuged under the same conditions. Finally, the supernatant was removed, and the cell pellets were resuspended in 3 mL of complete DMEM. Cells were counted on an Accuri C6 cytometer, and 1 million lymphocytes per mouse were deposed in 24 well-plates. cell stimulation cocktail (PMA/ionomycin, Invitrogen, USA) was added to stimulate immune cells, and plates were incubated at 37°C for 48 h under 10% of CO2. At The end, supernatants were collected and stored at -80°C until use. Cytokines were determined using a T helper cytokine panel LEGENDPLEX assay (IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17A, IL-17F, IL-22, IFN-γ, and TNF-α; BioLegend, USA) according to the manufacturer’s instructions. The samples were read and analyzed as explained above.

SCFA determination in cecum samples

The day of the sacrifice, cecal samples were collected and placed in liquid nitrogen at −80 °C. SCFA were extracted from the samples with water (wt g/vol) and centrifuged for 15 min at 15000xg. Supernatants were collected and deproteinized overnight at 4°C by the addition of phosphotungstic acid (10%, Sigma-Aldrich, USA). The samples were processed and analyzed as described by Kropp et al.32.

DNA extraction in feces

Mouse feces were sampled at three time points: day 0 (T0), 14 (T14), and 17 (T17) (Supplementary Fig. 4) and stored at −80 °C until total genomic DNA extraction using Godon’s protocol77. Feces were suspended in 250 µL of 4 M guanidine thiocyanate (Sigma-Aldrich, USA) and 40 µL of 10% N-lauroyl sarcosine (Sigma-Aldrich, USA) solution. Samples were vortexed and incubated for 10 min at room temperature. Then, 500 µL of 5% N-lauroyl sarcosine was added, and samples were incubated 1 h at 60°C under agitation. 0.1 mm beads were used for bacterial cell lysis, and feces were homogenized three cycles of 30 s at 10,000 rpm at 4 °C with Precellys® evolution coupled with Cryolys® (Ozyme, France) evolution. Subsequently, 20 mg polyvinylpyrrolidone (PVPP) (Sigma-Aldrich, USA) was added, and the suspension was centrifuged at 20,000 × g at 4 °C for 5 min. The supernatants were recovered in a separate tube. Pellets were washed twice with 650 μL of a 6,5 pH 1 M Tric-Cl, 0,5 M EDTA, 5 M NaCl, 1% PVPP, and mQ water solution (TENP buffer), centrifuged, and supernatants were recovered in the same tube. The pooled supernatants were centrifuged at 20,000 × g and 4 °C for 1 min. Nucleic acids were precipitated using isopropanol. Following 10 min incubation at room temperature, the pool was centrifuged at 20,000 × g at 4 °C for 10 min, and the pellet was resuspended in 450 µL of a pH 8 0,1 M phosphate buffer. Fifty µL of M potassium acetate 5 M solution was added, and samples were left at 4 °C overnight. Finally, samples were centrifuged at 20,000xg at 4 °C for 30 min. supernatants were collected, and 2 μL of RNAse (10 mg/mL, Fisher Scientific) was added and incubated at 36 °C for 30 min. DNA was precipitated using 50 μL of 3 M sodium acetate and 1000 µL ice-cold 100% ethanol. Samples were centrifuged at 20,000 x g for 10 min at 4 °C the pellets were washed in 60% ethanol two times, dried, and stored at −20 °C in TE buffer.

Microbiota determinations by 16S rRNA sequencing from fecal content

The 16S rRNA gene segments spanning the variable V3 and V4 regions were amplified from fecal DNA using the Herculase II Fusion DNA Polymerase Nextera XT Index Kit V2 with the primers Bakt_341F 5′- CCTACGGGNGGCWGCAG -3′ and Bakt_805R 5′- GACTACHVGGGTATCTAATCC -3′78. The V3-V4 amplicons were prepared according to the 16S Metagenomic Sequencing Library Preparation Part #15044223 Rev. B and sequenced on an Illumina MiSeq platform. Sequences were processed using version 2 of the Quantitative Insights into Microbial Ecology (QIIME2) pipeline79. Cleaned sequencing reads were obtained after removing the barcode sequences, primers, and low-quality reads (Q < 30). The cleaned 16S rRNA gene sequences were processed using amplicon sequence variants (ASVs). Taxonomic assignment of the ASVs was performed using the primer-specific trained version of the GreenGenes2 Database80.

Polymerase chain reactions (PCR) to detect C. minuta

To confirm the results obtained after 16S sequencing of the fecal content regarding the presence of C. minuta, we decided to perform a PCR with primers specific for the amplification of C. minuta according to Jinthas and co workers81 on the gDNA samples of day 21 used for the microbiota analysis. Negative controls were also included (mouse gDNA, water and another bacterium).

RNA isolation and colon transcriptome analysis

One centimeter section of the distal colon (n = 80) was placed in RNA later (ThermoFisher Scientific, USA), frozen in liquid nitrogen, and stored at -80°C before RNA extraction using RNeasy mini kit (Qiagen, Germany) according to manufacturer’s specifications. RNA samples were checked for quality control, and qualified samples were used for library construction using the TruSeq Stranded Total RNA LT Sample Prep Kit (Human, Mouse, Rat, Illumina). The ribo-depleted fractions of the prepared libraries were paired-end sequenced (2 × 150 bp) on a NovaSeq6000 Illumina platform with a target sequencing yield of 50 million reads per sample. Cleaned sequencing reads were obtained after removing low-quality sections (Phred score < 33), reads shorter than 36 bp, and reads adapter. Contaminants (humans and microorganisms) were also eliminated, following the guidelines recommended by Kraken 2 (Wood, Lu, and Langmead 2019) recommended guidelines. The processed reads were then aligned and annotated based on the GRCm39 assembly version using STAR v2.6.9a (Dobin et al. 2013).

Lowly expressed genes were filtered out following the best practice recommended in edgeR v.3.14.1, using the filterByExpr function82. Prior to gene expression analysis, we examined potential outliers using a Mahalanobis distance83 and applied Bonferroni correction for multiple test comparisons.

Transcriptomic analysis was uploaded to Qiagen’s IPA system for core analysis and then overlaid with the global molecular network in the Ingenuity Pathway Knowledge Base (IPKB). IPA was performed to identify canonical pathways and gene networks that were differentially expressed after DSM 22607 administration compared with DNBS-Vehicle.

Quantitative reverse transcription (RT)-qPCR

Total RNA from each sample was reverse-transcribed using a high-capacity RNA-to-cDNA kit (ThermoFisher Scientific, USA). qPCR reactions were performed with the ROX probe 1X MasterMix dTTP blue (Takyon, Eurogentec, Belgium), primers with probe (Thermo Fisher Scientific, USA), and 125 ng of cDNA. The genes analyzed were TNF receptor superfamily member 8 (Tnfrsf8), junction plakoglobin (jup), interleukine-33 (il-33), myeloid differentiation primary response 88 (myd88), and the housekeeping gene TATA-box-binding protein (tbp). Amplification was performed using the StepOneTM Real-Time qPCR system (Applied Biosystems, USA). Cycle threshold (Ct) values were used to calculate fold-change values, according to Rao et al.84.

Statistical analysis

All results are expressed as the mean ± standard error of the mean (SEM). Statistical analyses were performed using GraphPad Prism version 9.4.0 (GraphPad Software, La Jolla, CA, USA). The observed differences were analyzed for statistical significance using one-way analysis of variance with the Original FDR method of Benjamini and Hochberg multiple comparison post-hoc tests or Kruskal–Wallis test with Dunn’s multiple comparisons as post-hoc tests. The differences were considered significant at *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Supplementary information

Supplemental material

Supplementary information

The online version contains supplementary material available at 10.1038/s41522-024-00540-6.

Acknowledgements

This work benefited from the facilities and expertize of @BRIDGe (Université Paris-Saclay, INRAE, AgroParisTech, GABI, 78350 Jouy-en-Josas, France). We wish to thank the staff of the INRAE Infectiology of Fishes and Rodents Facility (IERP-UE907, Jouy-en-Josas Research Center, France) for performing animal experiments. The IERP Facility belongs to the National Distributed Research Infrastructure for the Control of Animal and Zoonotic Emerging Infectious Diseases through an In Vivo Investigation. We also wanted to thank Carla Dos ANjos De Souza from DataOmics for the support on the bioinformatic analysis.

Author contributions

C.K., K.T., S.C. and R.M. performed experiments. P.L., S.P.C., and R.M. conceived and supervised the study. C.K. wrote the first draft of the manuscript. P.L., S.P.C., and R.M. corrected the manuscript. All authors have read and accepted the manuscript.

Data availability

The 16S RNA raw reads and transcriptomic raw data are available at 10.57745/XXAXFA and 10.57745/02ODSE respectively.

Competing interests

C.K. and S.C. were employees of Ysopia Bioscience. Founders participated in the study design. P.L. reports lecture fee, board membership, or consultancy from Biose, Biostime, Boiron, Bonduelle, BMS, Bromatech, IPSEN, iTaK, Lallemand, Lesaffre, L’Oréal, Mayoli, Merck, Procter and Gamble, Second Genome, Therascience and URGO and is co-founder of Exeliom Biosciences. RM declares no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Patel RM Underwood MA Probiotics and necrotizing enterocolitis Semin. Pediatr. Surg. 2018 27 39 46 10.1053/j.sempedsurg.2017.11.008 29275816
Patel, R. M. & Underwood, M. A. Probiotics and necrotizing enterocolitis. Semin. Pediatr. Surg. 27, 39–46 (2018).29275816
2. Filidou E Kolios G Probiotics in intestinal mucosal healing: a new therapy or an old friend? Pharmaceuticals (Basel) 2021 14 1181 10.3390/ph14111181 34832962
Filidou, E. & Kolios, G. Probiotics in intestinal mucosal healing: a new therapy or an old friend? Pharmaceuticals (Basel) 14, 1181 (2021).34832962
3. Simon E Călinoiu LF Mitrea L Vodnar DC Probiotics, prebiotics, and synbiotics: implications and beneficial effects against irritable bowel syndrome Nutrients 2021 13 2112 10.3390/nu13062112 34203002
Simon, E., Călinoiu, L. F., Mitrea, L. & Vodnar, D. C. Probiotics, prebiotics, and synbiotics: implications and beneficial effects against irritable bowel syndrome. Nutrients 13, 2112 (2021).34203002
4. Jakubczyk D Leszczyńska K Górska S The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)—a critical review Nutrients 2020 12 1973 10.3390/nu12071973 32630805
Jakubczyk, D., Leszczyńska, K. & Górska, S. The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)—a critical review. Nutrients 12, 1973 (2020).32630805
5. Sheykhsaran, E. et al. Gut microbiota and obesity: an overview of microbiota to microbial-based therapies. Postgrad. Med. J. 99, 384–402 (2022).
6. Lee M Chang EB Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues Gastroenterology 2021 160 524 537 10.1053/j.gastro.2020.09.056 33253681
Lee, M. & Chang, E. B. Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues. Gastroenterology 160, 524–537 (2021).33253681
7. Abraham C Cho JH Inflammatory bowel disease N. Engl. J. Med. 2009 361 2066 2078 10.1056/NEJMra0804647 19923578
Abraham, C. & Cho, J. H. Inflammatory bowel disease. N. Engl. J. Med. 361, 2066–2078 (2009).19923578
8. Stokkers PCF Hommes DW New cytokine therapeutics for inflammatory bowel disease Cytokine 2004 28 167 173 10.1016/j.cyto.2004.07.012 15588691
Stokkers, P. C. F. & Hommes, D. W. New cytokine therapeutics for inflammatory bowel disease. Cytokine 28, 167–173 (2004).15588691
9. Fernández-Tomé S Ortega Moreno L Chaparro M Gisbert JP Gut microbiota and dietary factors as modulators of the mucus layer in inflammatory bowel disease Int. J. Mol. Sci. 2021 22 10224 10.3390/ijms221910224 34638564
Fernández-Tomé, S., Ortega Moreno, L., Chaparro, M. & Gisbert, J. P. Gut microbiota and dietary factors as modulators of the mucus layer in inflammatory bowel disease. Int. J. Mol. Sci. 22, 10224 (2021).34638564
10. Yang S Yu M Role of goblet cells in intestinal barrier and mucosal immunity J. Inflamm. Res. 2021 14 3171 3183 10.2147/JIR.S318327 34285541
Yang, S. & Yu, M. Role of goblet cells in intestinal barrier and mucosal immunity. J. Inflamm. Res. 14, 3171–3183 (2021).34285541
11. Michielan A D’Incà R Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut Mediators Inflamm. 2015 2015 628157 10.1155/2015/628157 26582965
Michielan, A. & D’Incà, R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015, 628157 (2015).26582965
12. Gong D Gong X Wang L Yu X Dong Q Involvement of reduced microbial diversity in inflammatory bowel disease Gastroenterol. Res. Pract. 2016 2016 6951091 10.1155/2016/6951091 28074093
Gong, D., Gong, X., Wang, L., Yu, X. & Dong, Q. Involvement of reduced microbial diversity in inflammatory bowel disease. Gastroenterol. Res. Pract. 2016, 6951091 (2016).28074093
13. Nishida A Gut microbiota in the pathogenesis of inflammatory bowel disease Clin. J. Gastroenterol. 2018 11 1 10 10.1007/s12328-017-0813-5 29285689
Nishida, A. et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin. J. Gastroenterol. 11, 1–10 (2018).29285689
14. Seksik P Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon Gut 2003 52 237 242 10.1136/gut.52.2.237 12524406
Seksik, P. Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut 52, 237–242 (2003).12524406
15. Sokol H Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn’s disease Gut 2020 69 462 472 10.1136/gutjnl-2019-318719 31142586
Sokol, H. et al. Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn’s disease. Gut 69, 462–472 (2020).31142586
16. Baldelli V Scaldaferri F Putignani L Del Chierico F The role of enterobacteriaceae in gut microbiota dysbiosis in inflammatory bowel diseases Microorganisms 2021 9 697 10.3390/microorganisms9040697 33801755
Baldelli, V., Scaldaferri, F., Putignani, L. & Del Chierico, F. The role of enterobacteriaceae in gut microbiota dysbiosis in inflammatory bowel diseases. Microorganisms 9, 697 (2021).33801755
17. Nomura K Bacteroidetes species are correlated with disease activity in ulcerative colitis J. Clin. Med. 2021 10 1749 10.3390/jcm10081749 33920646
Nomura, K. et al. Bacteroidetes species are correlated with disease activity in ulcerative colitis. J. Clin. Med. 10, 1749 (2021).33920646
18. Gkouskou KK Deligianni C Tsatsanis C Eliopoulos AG The gut microbiota in mouse models of inflammatory bowel disease Front Cell Infect. Microbiol. 2014 4 28 10.3389/fcimb.2014.00028 24616886
Gkouskou, K. K., Deligianni, C., Tsatsanis, C. & Eliopoulos, A. G. The gut microbiota in mouse models of inflammatory bowel disease. Front Cell Infect. Microbiol. 4, 28 (2014).24616886
19. Sokol H Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients Proc. Natl Acad. Sci. USA 2008 105 16731 16736 10.1073/pnas.0804812105 18936492
Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. USA 105, 16731–16736 (2008).18936492
20. Halfvarson J Dynamics of the human gut microbiome in inflammatory bowel disease Nat. Microbiol. 2017 2 17004 10.1038/nmicrobiol.2017.4 28191884
Halfvarson, J. et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat. Microbiol. 2, 17004 (2017).28191884
21. Rehman A Geographical patterns of the standing and active human gut microbiome in health and IBD Gut 2016 65 238 248 10.1136/gutjnl-2014-308341 25567118
Rehman, A. et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut 65, 238–248 (2016).25567118
22. Sultan S Metabolic influences of gut microbiota dysbiosis on inflammatory bowel disease Front Physiol. 2021 12 715506 10.3389/fphys.2021.715506 34646151
Sultan, S. et al. Metabolic influences of gut microbiota dysbiosis on inflammatory bowel disease. Front Physiol. 12, 715506 (2021).34646151
23. Braun T Individualized dynamics in the gut microbiota precede Crohnʼs disease flares Am. J. Gastroenterol. 2019 114 1142 1151 10.14309/ajg.0000000000000136 30741738
Braun, T. et al. Individualized dynamics in the gut microbiota precede Crohnʼs disease flares. Am. J. Gastroenterol. 114, 1142–1151 (2019).30741738
24. Teofani A Intestinal taxa abundance and diversity in inflammatory bowel disease patients: an analysis including covariates and confounders Nutrients 2022 14 260 10.3390/nu14020260 35057440
Teofani, A. et al. Intestinal taxa abundance and diversity in inflammatory bowel disease patients: an analysis including covariates and confounders. Nutrients 14, 260 (2022).35057440
25. Pittayanon R Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review Gastroenterology 2020 158 930 946.e1 10.1053/j.gastro.2019.11.294 31812509
Pittayanon, R. et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology 158, 930–946.e1 (2020).31812509
26. Goodrich JK Human genetics shape the gut microbiome Cell 2014 159 789 799 10.1016/j.cell.2014.09.053 25417156
Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159, 789–799 (2014).25417156
27. Mazier W A new strain of christensenella minuta as a potential biotherapy for obesity and associated metabolic diseases Cells 2021 10 823 10.3390/cells10040823 33917566
Mazier, W. et al. A new strain of christensenella minuta as a potential biotherapy for obesity and associated metabolic diseases. Cells 10, 823 (2021).33917566
28. Alard J New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches Beneficial. Microbe. 2018 9 317 331 10.3920/BM2017.0097
Alard, J. et al. New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches. Beneficial. Microbe. 9, 317–331 (2018).
29. Mancabelli, L. et al. Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. FEMS Microbiol. Ecol. 93, fix153 (2017).
30. Banerjee S Schlaeppi K van der Heijden MGA Keystone taxa as drivers of microbiome structure and functioning Nat. Rev. Microbiol 2018 16 567 576 10.1038/s41579-018-0024-1 29789680
Banerjee, S., Schlaeppi, K. & van der Heijden, M. G. A. Keystone taxa as drivers of microbiome structure and functioning. Nat. Rev. Microbiol.16, 567–576 (2018).29789680
31. Tudela H Claus SP Saleh M Next generation microbiome research: identification of keystone species in the metabolic regulation of host-gut microbiota interplay Front Cell Dev. Biol. 2021 9 719072 10.3389/fcell.2021.719072 34540837
Tudela, H., Claus, S. P. & Saleh, M. Next generation microbiome research: identification of keystone species in the metabolic regulation of host-gut microbiota interplay. Front Cell Dev. Biol. 9, 719072 (2021).34540837
32. Kropp C The Keystone commensal bacterium christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo Sci. Rep. 2021 11 11494 10.1038/s41598-021-90885-1 34075098
Kropp, C. et al. The Keystone commensal bacterium christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo. Sci. Rep. 11, 11494 (2021).34075098
33. Morampudi, V. et al. DNBS/TNBS colitis models: providing insights into inflammatory bowel disease and effects of dietary fat. J. Vis. Exp. 27, e51297 (2014).
34. Croft M TNF superfamily in inflammatory disease: translating basic insights Trends Immunol. 2012 33 144 152 10.1016/j.it.2011.10.004 22169337
Croft, M. et al. TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol. 33, 144–152 (2012).22169337
35. Xu L IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice Biotechnol. Lett. 2020 42 1113 1121 10.1007/s10529-020-02815-2 32140881
Xu, L. et al. IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice. Biotechnol. Lett. 42, 1113–1121 (2020).32140881
36. Nagpal R Yadav H Bacterial translocation from the gut to the distant organs: an overview ANM 2017 71 11 16
Nagpal, R. & Yadav, H. Bacterial translocation from the gut to the distant organs: an overview. ANM 71, 11–16 (2017).
37. Hu J-CE Expression of tricellular tight junction proteins and the paracellular macromolecule barrier are recovered in remission of ulcerative colitis BMC Gastroenterol. 2021 21 141 10.1186/s12876-021-01723-7 33789594
Hu, J.-C. E. et al. Expression of tricellular tight junction proteins and the paracellular macromolecule barrier are recovered in remission of ulcerative colitis. BMC Gastroenterol. 21, 141 (2021).33789594
38. Clarke LL A guide to Ussing chamber studies of mouse intestine Am. J. Physiol. Gastrointest. Liver Physiol. 2009 296 G1151 G1166 10.1152/ajpgi.90649.2008 19342508
Clarke, L. L. A guide to Ussing chamber studies of mouse intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1151–G1166 (2009).19342508
39. Al-Sadi R Bifidobacterium bifidum enhances the intestinal epithelial tight junction barrier and protects against intestinal inflammation by targeting the toll-like receptor-2 pathway in an NF-κB-independent manner Int. J. Mol. Sci. 2021 22 8070 10.3390/ijms22158070 34360835
Al-Sadi, R. et al. Bifidobacterium bifidum enhances the intestinal epithelial tight junction barrier and protects against intestinal inflammation by targeting the toll-like receptor-2 pathway in an NF-κB-independent manner. Int. J. Mol. Sci. 22, 8070 (2021).34360835
40. Schlegel N Boerner K Waschke J Targeting desmosomal adhesion and signalling for intestinal barrier stabilization in inflammatory bowel diseases-lessons from experimental models and patients Acta. Physiol. (Oxf) 2021 231 e13492 10.1111/apha.13492 32419327
Schlegel, N., Boerner, K. & Waschke, J. Targeting desmosomal adhesion and signalling for intestinal barrier stabilization in inflammatory bowel diseases-lessons from experimental models and patients. Acta. Physiol. (Oxf) 231, e13492 (2021).32419327
41. Cornick S Tawiah A Chadee K Roles and regulation of the mucus barrier in the gut Tissue Barriers 2015 3 e982426 10.4161/21688370.2014.982426 25838985
Cornick, S., Tawiah, A. & Chadee, K. Roles and regulation of the mucus barrier in the gut. Tissue Barriers 3, e982426 (2015).25838985
42. Vancamelbeke M Vermeire S The intestinal barrier: a fundamental role in health and disease Expert Rev. Gastroenterol. Hepatol. 2017 11 821 834 10.1080/17474124.2017.1343143 28650209
Vancamelbeke, M. & Vermeire, S. The intestinal barrier: a fundamental role in health and disease. Expert Rev. Gastroenterol. Hepatol. 11, 821–834 (2017).28650209
43. Murata Y Ishiguro Y Itoh J Munakata A Yoshida Y The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis J. Gastroenterol. 1995 30 56 60 8563892
Murata, Y., Ishiguro, Y., Itoh, J., Munakata, A. & Yoshida, Y. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J. Gastroenterol. 30, 56–60 (1995).8563892
44. Singh S Anshita D Ravichandiran V MCP-1: Function, regulation, and involvement in disease Int. Immunopharmacol. 2021 101 107598 10.1016/j.intimp.2021.107598 34233864
Singh, S., Anshita, D. & Ravichandiran, V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol. 101, 107598 (2021).34233864
45. Watanabe S Kawamoto S Ohtani N Hara E Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases Cancer Sci. 2017 108 563 569 10.1111/cas.13184 28165648
Watanabe, S., Kawamoto, S., Ohtani, N. & Hara, E. Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases. Cancer Sci. 108, 563–569 (2017).28165648
46. Pyrillou K Burzynski LC Clarke MCH Alternative pathways of IL-1 activation, and its role in health and disease Front Immunol. 2020 11 613170 10.3389/fimmu.2020.613170 33391283
Pyrillou, K., Burzynski, L. C. & Clarke, M. C. H. Alternative pathways of IL-1 activation, and its role in health and disease. Front Immunol. 11, 613170 (2020).33391283
47. Qu S Akkermansia muciniphila alleviates dextran sulfate sodium (DSS)-induced acute colitis by NLRP3 activation Microbiol. Spectr. 2021 9 e0073021 10.1128/Spectrum.00730-21 34612661
Qu, S. et al. Akkermansia muciniphila alleviates dextran sulfate sodium (DSS)-induced acute colitis by NLRP3 activation. Microbiol. Spectr. 9, e0073021 (2021).34612661
48. Ghyselinck J A 4-strain probiotic supplement influences gut microbiota composition and gut wall function in patients with ulcerative colitis Int. J. Pharm. 2020 587 119648 10.1016/j.ijpharm.2020.119648 32679260
Ghyselinck, J. et al. A 4-strain probiotic supplement influences gut microbiota composition and gut wall function in patients with ulcerative colitis. Int. J. Pharm. 587, 119648 (2020).32679260
49. Geremia A Biancheri P Allan P Corazza GR Di Sabatino A Innate and adaptive immunity in inflammatory bowel disease Autoimmun. Rev. 2014 13 3 10 10.1016/j.autrev.2013.06.004 23774107
Geremia, A., Biancheri, P., Allan, P., Corazza, G. R. & Di Sabatino, A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun. Rev. 13, 3–10 (2014).23774107
50. Kawashima K Evaluation of the relationship between the spleen volume and the disease activity in ulcerative colitis and Crohn disease Medicine (Baltimore) 2022 101 e28515 10.1097/MD.0000000000028515 35029912
Kawashima, K. et al. Evaluation of the relationship between the spleen volume and the disease activity in ulcerative colitis and Crohn disease. Medicine (Baltimore) 101, e28515 (2022).35029912
51. Shapouri-Moghaddam A Macrophage plasticity, polarization, and function in health and disease J. Cell Physiol. 2018 233 6425 6440 10.1002/jcp.26429 29319160
Shapouri-Moghaddam, A. et al. Macrophage plasticity, polarization, and function in health and disease. J. Cell Physiol. 233, 6425–6440 (2018).29319160
52. Peyrin-Biroulet L Anti-TNF therapy in inflammatory bowel diseases: a huge review Minerva. Gastroenterol. Dietol. 2010 56 233 243 20485259
Peyrin-Biroulet, L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva. Gastroenterol. Dietol. 56, 233–243 (2010).20485259
53. Hayden MS Ghosh S Regulation of NF-κB by TNF family cytokines Semin. Immunol. 2014 26 253 266 10.1016/j.smim.2014.05.004 24958609
Hayden, M. S. & Ghosh, S. Regulation of NF-κB by TNF family cytokines. Semin. Immunol. 26, 253–266 (2014).24958609
54. Chudnow ML Levy MB Kelly KJ Binion DG Increased prevalence of environmental allergy in patients with Crohn’s disease J. Allergy Clin. Immunol. 2004 113 S276 10.1016/j.jaci.2004.01.468
Chudnow, M. L., Levy, M. B., Kelly, K. J. & Binion, D. G. Increased prevalence of environmental allergy in patients with Crohn’s disease. J. Allergy Clin. Immunol. 113, S276 (2004).
55. León, B. & Ballesteros-Tato, A. Modulating Th2 cell immunity for the treatment of asthma. Front. Immunol. 12, 637948 (2021).
56. Mizoguchi A Mizoguchi E Bhan AK The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor α mutant mice Gastroenterology 1999 116 320 326 10.1016/S0016-5085(99)70128-9 9922312
Mizoguchi, A., Mizoguchi, E. & Bhan, A. K. The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor α mutant mice. Gastroenterology 116, 320–326 (1999).9922312
57. Schreiber S Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease Gastroenterology 2021 160 2354 2366.e11 10.1053/j.gastro.2021.02.062 33667488
Schreiber, S. et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology 160, 2354–2366.e11 (2021).33667488
58. Collado MC Derrien M Isolauri E de Vos WM Salminen S Intestinal integrity and akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly Appl. Environ. Microbiol. 2007 73 7767 7770 10.1128/AEM.01477-07 17933936
Collado, M. C., Derrien, M., Isolauri, E., de Vos, W. M. & Salminen, S. Intestinal integrity and akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl. Environ. Microbiol. 73, 7767–7770 (2007).17933936
59. Wan F Dihydroquercetin supplement alleviates colonic inflammation potentially through improved gut microbiota community in mice Food Funct. 2021 12 11420 11434 10.1039/D1FO01422F 34673859
Wan, F. et al. Dihydroquercetin supplement alleviates colonic inflammation potentially through improved gut microbiota community in mice. Food Funct. 12, 11420–11434 (2021).34673859
60. Xue L The effects of live and pasteurized akkermansia muciniphila on DSS-induced ulcerative colitis, gut microbiota, and metabolomics in mice Food Funct. 2023 14 4632 4646 10.1039/D2FO03493J 37098829
Xue, L. et al. The effects of live and pasteurized akkermansia muciniphila on DSS-induced ulcerative colitis, gut microbiota, and metabolomics in mice. Food Funct. 14, 4632–4646 (2023).37098829
61. Zhai R Strain-specific anti-inflammatory properties of two akkermansia muciniphila strains on chronic colitis in mice Front. Cell. Infect. Microbiol. 2019 9 239 10.3389/fcimb.2019.00239 31334133
Zhai, R. et al. Strain-specific anti-inflammatory properties of two akkermansia muciniphila strains on chronic colitis in mice. Front. Cell. Infect. Microbiol. 9, 239 (2019).31334133
62. Burger-van Paassen N The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection Biochem. J. 2009 420 211 219 10.1042/BJ20082222 19228118
Burger-van Paassen, N. et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem. J. 420, 211–219 (2009).19228118
63. Pérez-Reytor D Puebla C Karahanian E García K Use of short-chain fatty acids for the recovery of the intestinal epithelial barrier affected by bacterial toxins Front Physiol. 2021 12 650313 10.3389/fphys.2021.650313 34108884
Pérez-Reytor, D., Puebla, C., Karahanian, E. & García, K. Use of short-chain fatty acids for the recovery of the intestinal epithelial barrier affected by bacterial toxins. Front Physiol. 12, 650313 (2021).34108884
64. Berni Canani R The potential therapeutic efficacy of lactobacillus GG in children with food allergies Pharmaceuticals 2012 5 655 664 10.3390/ph5060655 24281667
Berni Canani, R. et al. The potential therapeutic efficacy of lactobacillus GG in children with food allergies. Pharmaceuticals 5, 655–664 (2012).24281667
65. Yan Y A combination of baicalin and berberine hydrochloride aeliorates dextran sulfate sodium-induced colitis by modulating colon gut microbiota J. Med. Food 2022 25 853 862 10.1089/jmf.2021.K.0173 35980327
Yan, Y. et al. A combination of baicalin and berberine hydrochloride aeliorates dextran sulfate sodium-induced colitis by modulating colon gut microbiota. J. Med. Food 25, 853–862 (2022).35980327
66. Qin N Polysaccharides from the seeds of Gleditsia sinensis Lam. attenuate DSS-induced colitis in mice via improving gut barrier homeostasis and alleviating gut microbiota dybiosis Food Funct. 2023 14 122 132 10.1039/D2FO02722D 36510766
Qin, N. et al. Polysaccharides from the seeds of Gleditsia sinensis Lam. attenuate DSS-induced colitis in mice via improving gut barrier homeostasis and alleviating gut microbiota dybiosis. Food Funct. 14, 122–132 (2023).36510766
67. Sun X A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice Gastroenterology 2008 134 447 458 10.1053/j.gastro.2007.11.004 18242212
Sun, X. et al. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology 134, 447–458 (2008).18242212
68. Na HJ Hudson SA Bochner BS IL-33 enhances siglec-8 mediated apoptosis of human eosinophils Cytokine 2012 57 169 174 10.1016/j.cyto.2011.10.007 22079334
Na, H. J., Hudson, S. A. & Bochner, B. S. IL-33 enhances siglec-8 mediated apoptosis of human eosinophils. Cytokine 57, 169–174 (2012).22079334
69. Ngo Thi Phuong, N. et al. IL-33 drives expansion of type 2 innate lymphoid cells and regulatory T cells and protects mice from severe, acute colitis. Front. Immunol. 12, 669787 (2021).
70. He X Bai Y Zhou H Wu K Akkermansia muciniphila alters gut microbiota and immune system to improve cardiovascular diseases in murine model Front Microbiol. 2022 13 906920 10.3389/fmicb.2022.906920 35774450
He, X., Bai, Y., Zhou, H. & Wu, K. Akkermansia muciniphila alters gut microbiota and immune system to improve cardiovascular diseases in murine model. Front Microbiol. 13, 906920 (2022).35774450
71. Arifuzzaman M Inulin fibre promotes microbiota-derived bile acids and type 2 inflammation Nature 2022 611 578 584 10.1038/s41586-022-05380-y 36323778
Arifuzzaman, M. et al. Inulin fibre promotes microbiota-derived bile acids and type 2 inflammation. Nature 611, 578–584 (2022).36323778
72. Ameho CK Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor α production in trinitrobenzene sulphonic acid induced colitis Gut 1997 41 487 493 10.1136/gut.41.4.487 9391247
Ameho, C. K. et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor α production in trinitrobenzene sulphonic acid induced colitis. Gut 41, 487–493 (1997).9391247
73. Wallace JL MacNaughton WK Morris GP Beck PL Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease Gastroenterology 1989 96 29 36 10.1016/0016-5085(89)90760-9 2535830
Wallace, J. L., MacNaughton, W. K., Morris, G. P. & Beck, P. L. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96, 29–36 (1989).2535830
74. Barone, M. et al. A versatile new model of chemically induced chronic colitis using an outbred murine strain. Front. Microbiol. 9, 565 (2018).
75. Tomas J Early colonizing Escherichia coli elicits remodeling of rat colonic epithelium shifting toward a new homeostatic state ISME J. 2015 9 46 58 10.1038/ismej.2014.111 25012905
Tomas, J. et al. Early colonizing Escherichia coli elicits remodeling of rat colonic epithelium shifting toward a new homeostatic state. ISME J. 9, 46–58 (2015).25012905
76. Howat WJ Wilson BA Tissue fixation and the effect of molecular fixatives on downstream staining procedures Methods 2014 70 12 19 10.1016/j.ymeth.2014.01.022 24561827
Howat, W. J. & Wilson, B. A. Tissue fixation and the effect of molecular fixatives on downstream staining procedures. Methods 70, 12–19 (2014).24561827
77. Godon JJ Zumstein E Dabert P Habouzit F Moletta R Molecular microbial diversity of an anaerobic digestor as determined by small-subunit rDNA sequence analysis Appl. Environ. Microbiol. 1997 63 2802 2813 10.1128/aem.63.7.2802-2813.1997 9212428
Godon, J. J., Zumstein, E., Dabert, P., Habouzit, F. & Moletta, R. Molecular microbial diversity of an anaerobic digestor as determined by small-subunit rDNA sequence analysis. Appl. Environ. Microbiol. 63, 2802–2813 (1997).9212428
78. Sinclair L Osman OA Bertilsson S Eiler A Microbial community composition and diversity via 16S rRNA gene amplicons: evaluating the illumina platform PLoS ONE 2015 10 e0116955 10.1371/journal.pone.0116955 25647581
Sinclair, L., Osman, O. A., Bertilsson, S. & Eiler, A. Microbial community composition and diversity via 16S rRNA gene amplicons: evaluating the illumina platform. PLoS ONE 10, e0116955 (2015).25647581
79. Almeida A Mitchell AL Tarkowska A Finn RD Benchmarking taxonomic assignments based on 16S rRNA gene profiling of the microbiota from commonly sampled environments GigaScience 2018 7 giy054 10.1093/gigascience/giy054 29762668
Almeida, A., Mitchell, A. L., Tarkowska, A. & Finn, R. D. Benchmarking taxonomic assignments based on 16S rRNA gene profiling of the microbiota from commonly sampled environments. GigaScience 7, giy054 (2018).29762668
80. McDonald, D. et al. Greengenes2 unifies microbial data in a single reference tree. Nat. Biotechnol. 42, 715–718 (2023).
81. Jinatham, V., Kullawong, N., Kespechara, K., Gentekaki, E. & Popluechai, S. Comparison of gut microbiota between lean and obese adult Thai individuals. 46, 277–287 (2018).
82. Robinson MD McCarthy DJ Smyth GK edgeR: a bioconductor package for differential expression analysis of digital gene expression data Bioinformatics 2010 26 139 140 10.1093/bioinformatics/btp616 19910308
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).19910308
83. Suzuki H Sota M Brown CJ Top EM Using mahalanobis distance to compare genomic signatures between bacterial plasmids and chromosomes Nucleic Acids Res. 2008 36 e147 10.1093/nar/gkn753 18953039
Suzuki, H., Sota, M., Brown, C. J. & Top, E. M. Using mahalanobis distance to compare genomic signatures between bacterial plasmids and chromosomes. Nucleic Acids Res. 36, e147 (2008).18953039
84. Rao X Huang X Zhou Z Lin X An improvement of the 2ˆ(–delta delta CT) method for quantitative real-time polymerase chain reaction data analysis Biostat. Bioinforma. Biomath. 2013 3 71 85 25558171
Rao, X., Huang, X., Zhou, Z. & Lin, X. An improvement of the 2ˆ(–delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat. Bioinforma. Biomath. 3, 71–85 (2013).25558171
